Pain Therapeutics Inc. (PTIE)

6.12
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 6.12
Open 6.07
Day Low/High 6.05 / 6.31
52 Wk Low/High 3.10 / 12.80
Volume 66.89K
Avg Volume 654.90K
Exchange NASDAQ
Shares Outstanding 6.59M
Market Cap 41.40M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pain Therapeutics Reports Positive Regulatory Meeting For REMOXY™

Pain Therapeutics Reports Positive Regulatory Meeting For REMOXY™

Resubmission of the REMOXY NDA On-Track for Q1 2018

Pain Therapeutics Announces New Publication On Alzheimer's Disease

Pain Therapeutics Announces New Publication On Alzheimer's Disease

Peer-reviewed Publication Supports On-Going Clinical Development of PTI-125

Pain Therapeutics Announces Upcoming Meeting With FDA

Pain Therapeutics Announces Upcoming Meeting With FDA

Pre-NDA Meeting, November 14th for REMOXY™ ER

Pain Therapeutics Announces Successful Phase I Clinical Study For PTI-125

Pain Therapeutics Announces Successful Phase I Clinical Study For PTI-125

PTI-125 Is Well-Tolerated in First-in-human Clinical Study

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.

National Institute On Drug Abuse Awards Pain Therapeutics $2.2 Million Grant

National Institute On Drug Abuse Awards Pain Therapeutics $2.2 Million Grant

Provides Funding for FENROCK™, an Abuse-deterrent Pain Patch

Pain Therapeutics Announces FDA Has Cleared An Investigational New Drug (IND) Application For PTI-125

Pain Therapeutics Announces FDA Has Cleared An Investigational New Drug (IND) Application For PTI-125

Clinical Study Initiation Is Expected Shortly, with Funding by NIH

NIH Awards $1.7 Million Research Grant To Pain Therapeutics To Study Alzheimer's Disease

NIH Grant Will Support Clinical Testing of PTI-125, an Experimental Drug Candidate

Pain Therapeutics Announces Research Publication On Alzheimer's Disease

PTI-125, an Experimental Drug, Restored Receptor Function and Significantly Improved Working Memory and Spatial Ability in a Transgenic Mouse Model of Alzheimer's Disease

Pain Therapeutics Announces Reverse Stock Split

Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017

Pain Therapeutics Announces Positive Regulatory Guidance For REMOXY™ ER

- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -

Pain Therapeutics To Discuss REMOXY® ER With FDA

Pain Therapeutics To Discuss REMOXY® ER With FDA

FDA Meeting Set for February 13, 2017

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

Here's a technical look at how to trade some of the most active stocks on the market right now.

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.

Putting 2 Biotechs Under the Microscope

These low-dollar biotech stocks are making big moves Monday -- in opposite directions.

Complete Response Letter For REMOXY®

Complete Response Letter For REMOXY®

Company Will Host Conference Call Monday, September 26th at 9:00am EDT

Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed

Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed

No Change to September 25th PDUFA Date